Drug intelligence / Profile preview

CD 250

Development stage: Preclinical
Lead developer: Chodang Pharm

Overview

CD 250 is an investigational drug candidate currently being developed by Chodang Pharmaceutical Industry for the treatment of blood cancer (hematologic malignancies). As of early 2024, the program is in the preclinical research stage. Specific details regarding the drug's molecular target, mechanism of action, and modality (such as whether it is a small molecule or a biologic) have not been publicly disclosed by the developer. It is part of Chodang's early-stage oncology pipeline focused on addressing unmet needs in hematology.

Beyond the preview

Go deeper on CD 250.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD 250.

Explore the full profile